Human VEGF-R2/KDR Platinum ELISA

Description: The human VEGF-R2/KDR ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human VEGF-R2/KDR.

VEGF-A (also called VEGF) and its receptors represent the best characterized signalling pathway in developmental and tumour angiogenesis. VEGF-A binds to two receptor-tyrosine kinases: VEGFR-1/Flt-1 and VEGFR-2/KDR. VEGFR-2 is the major mediator of the mitogenic, angiogenic and permeability-enhancing effects of VEGF-A. The VEGFR's possess an approximately 750 amino acid residue extracellular domain, which is organized into seven immunoglobulin (Ig)- like folds. This extracellular domain is followed by a single transmembrane region, a juxtamembrane domain, a split tyrosine-kinase domain interrupted by a 70-amino acid kinase insert and a C-terminal tail. Alternative splicing or proteolytic processing of VEGFR's give rise to secreted variants of VEGFR-2, also called soluble VEGFR-2. Although the VEGFR's are primarily expressed in the vascular system, sensitive methods like sandwich ELISA's have allowed the detection of VEGFR expression in non-endothelial cells like hematopoietic stem cells.

Besides its putative role as a surrogate marker for tumour angiogenesis, naturally occurring sVEGFR-2 is a molecular regulator for VEGF and VEGFR signalling.

References: Ebos,J.M.; Lee,C.R.; Christensen,J.G.; Mutsaers,A.J.; Kerbel,R.S.. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc.Natl.Acad.Sci.U.S.A 2007;104:17069-17074. (Link)

Olsson,A.K.; Dimberg,A.; Kreuger,J.; Claesson-Welsh,L.. VEGF receptor signalling - in control of vascular function. Nat.Rev.Mol Cell Biol 2006;7:359-371. (Link)

Carmeliet,P.. Angiogenesis in health and disease. Nat.Med 2003;9:653-660. (Link)

Ebos,J.M.; Bocci,G.; Man,S.; Thorpe,P.E.; Hicklin,D.J.; Zhou,D.; Jia,X.; Kerbel,R.S.. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res. 2004;2:315-326. (Link)

Ebos,J.M.; Lee,C.R.; Bogdanovic,E.; Alami,J.; Van,Slyke P.; Francia,G.; Xu,P.; Mutsaers,A.J.; Dumont,D.J.; Kerbel,R.S.. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 2008;68:521-529. (Link)

Ferrara,N.; Kerbel,R.S.. Angiogenesis as a therapeutic target. Nature 2005;438:967-974. (Link)